Phase I study of histone deacetylase inhibitor (HDI) MS-275 in adults with refractory or relapsed hematologic malignancies.

被引：0
|
作者：
Gojo, I
Karp, JE
Mann, D
Rollins, S
Greer, J
Tidwell, ML
Zhai, SP
Figg, WD
Trepel, J
Ryan, Q
Sausville, E
机构：
[1] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[2] NCI, Bethesda, MD 20892 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2198
引用
收藏
页码：559A / 559A
页数：1
相关论文
共 50 条
  • [1] Phase I study of histone deacetylase inhibitor (HDI) MS-275 in adults with refractory or realpsed hematologic malignancies.
    Gojo, I
    Gore, SD
    Jiemjit, A
    Greer, J
    Tidwell, ML
    Sparreboom, A
    Figg, WD
    Heyman, MR
    Rollins, S
    Trepel, J
    Sausville, EA
    Karp, JE
    BLOOD, 2003, 102 (11) : 388A - 388A
  • [2] Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
    Gojo, Ivana
    Jiemjit, Anchalee
    Trepel, Jane B.
    Sparreboom, Alex
    Figg, William D.
    Rollins, Sandra
    Tidwell, Michael L.
    Greer, Jacqueline
    Chung, Eun Joo
    Lee, Min-Jung
    Gore, Steven D.
    Sausville, Edward A.
    Zwiebel, James
    Karp, Judith E.
    BLOOD, 2007, 109 (07) : 2781 - 2790
  • [3] Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies
    Kummar, Shivaani
    Gutierrez, Martin
    Gardner, Erin R.
    Donovan, Erin
    Hwang, Kyunghwa
    Chung, Eun Joo
    Lee, Min-Jung
    Maynard, Kim
    Kalnitskiy, Mikhail
    Chen, Alice
    Melillo, Giovanni
    Ryan, Qin C.
    Conley, Barbara
    Figg, William D.
    Trepel, Jane B.
    Zwiebel, James
    Doroshow, James H.
    Murgo, Anthony J.
    CLINICAL CANCER RESEARCH, 2007, 13 (18) : 5411 - 5417
  • [4] A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas
    Gore, Lia
    Rothenberg, Mace L.
    O'Bryant, Cindy L.
    Schultz, Mary Kay
    Sandler, Alan B.
    Coffin, Denise
    McCoy, Candice
    Schott, Astrid
    Scholz, Catherine
    Eckhardt, S. Gail
    CLINICAL CANCER RESEARCH, 2008, 14 (14) : 4517 - 4525
  • [5] Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma
    Ryan, QC
    Headlee, D
    Acharya, M
    Sparreboom, A
    Trepel, JB
    Ye, J
    Figg, WD
    Hwang, K
    Chung, EJ
    Murgo, A
    Melillo, G
    Elsayed, Y
    Monga, M
    Kalnitskiy, M
    Zwiebel, J
    Sausville, EA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) : 3912 - 3922
  • [6] Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275
    Annette Altmann
    Michael Eisenhut
    Ulrike Bauder-Wüst
    Annette Markert
    Vasileios Askoxylakis
    Holger Hess-Stumpp
    Uwe Haberkorn
    European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37 : 2286 - 2297
  • [7] Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumors
    Gore, L
    Holden, SN
    Basche, M
    Raj, SKS
    Arnold, I
    O'Bryant, C
    Witta, S
    Rohde, B
    McCoy, C
    Eckhardt, SG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 201S - 201S
  • [8] Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275
    Altmann, Annette
    Eisenhut, Michael
    Bauder-Wuest, Ulrike
    Markert, Annette
    Askoxylakis, Vasileios
    Hess-Stumpp, Holger
    Haberkorn, Uwe
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (12) : 2286 - 2297
  • [9] Phase I pharmacokinetic-pharmacodynamic trial of weekly MS-275, an oral histone deacetylase inhibitor
    Donovan, EA
    Ryan, Q
    Acharya, M
    Chung, E
    Trepel, J
    Maynard, K
    Sausville, E
    Murgo, A
    Melillo, G
    Conley, B
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 215S - 215S
  • [10] Phase I study of tezacitabine (FMdC) in patients with relapsed and refractory hematologic malignancies.
    Faderl, S
    Garcia-Manero, G
    Thomas, DA
    Cortes, J
    O'Brien, S
    Giles, FJ
    Koller, CA
    Beran, M
    Verstovsek, S
    Kwari, M
    Gandhi, V
    Plunkett, W
    Kantarjian, HM
    BLOOD, 2001, 98 (11) : 595A - 595A
12345